Lexeo Therapeutics, Inc.
LXEO· Nasdaq
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2023 | Q2 2022 |
|---|---|---|
| Net Income | -$13.44M | -$15.14M |
| EPS Diluted | -$8.30 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexeo Therapeutics, Inc. · CIK 1907108 · Engraved from SEC EDGAR